Adult tissue & PSC-derived organoid based drug evaluation service
Organoids are three-dimensional mini-organs artificially created in vitro replicating the cellular composition, structure, and functional specificity of the organ.
A high-tech and high-quality human iPSC-derived 3D organoid modeling service is provided, seamlessly integrating non-animal resources.
Lambda Biologics, Pioneering Excellence in Organoid Technology
Lambda Biologics specializes in cutting-edge organoid-based solutions, offering unparalleled services for the pharmaceutical and biotechnology industries.
Comprehensive support is provided for pre-clinical research and drug development, ensuring innovative and reliable results.
By leveraging advanced mimicking capabilities and diverse tissue sources, Disease Medeling provide researchers with deeper insights into drug efficacy and safety.
These solutions streamline the path from discovery to development, enhancing predictability and clinical success rates.
Organoids derived from adult stem cells isolated from specific tissues, such as the intestine, liver, lungs, salivary glands, and tonsils, can be used for drug evaluation and other research applications.
iPSC-derived organoid
Organoids generated from induced pluripotent stem cells (iPSCs) undergo differentiation and maturation processes to mimic specific organs, enabling the creation of models such as the brain, cardiac, kidney, skin, and retina.
Broad application of the Disease Medeling
Drug Screening: Efficiently evaluate the efficacy of compounds using organoid platforms.
Drug Toxicity Testing: Ensure safety with physiologically relevant toxicity assessments.
Disease Modeling: Replicate human disease conditions for precise pre-clinical studies.
Probiotics effect in Leaky Gut model
The restorative effect of probiotics co-culture on tight junctions in the LPS-induced Leaky gut organoid model.
Antiviral drug effect in SARS-CoV-2 infected Tonsil organoid
Accumulation of SARS-CoV-2 particles on the apical surface of tonsil organoids on day 3.
Inhibition of (Left) viral RNA titers and (Right) viral nucleocapsid gene expression on day 2 after treatment of SARS-CoV-2–infected organoids with increasing concentrations of remdesivir.
